According to the business intelligence report titled ‘Antiviral Drugs Market Size By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Indication (Influenza, HIV AIDS, Hepatitis, Herpes Simplex Virus [HSV], Coronavirus Infection), By Type (Branded, Generic), By Age Group (Pediatric, Adult, Geriatric), Industry Analysis Report, Regional Outlook, Type Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027’, available with Market Study Report, global antiviral drugs market is projected to record significant growth between 2021-2027.
 

Growing geriatric population, and surging cases of infectious diseases like seasonal flu and COVID-19 infections are key factors spurring global antiviral drugs industry development. Moreover, rising burden of sexually transmitted diseases along with presence of pipeline products to treat HIV is further aiding the market augmentation.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3692095/
 

For the unversed, antiviral drugs are prescription medicines that efficiently combat viruses in the human body. When consumed as directed, they help in decreasing the duration of flu symptoms in children and adults. They are available in three forms – pills, inhaled powder, and liquid.
 

Coming to the market restraints, presence of generic drugs, resistance to drugs in some patients, and growing awareness about preventive drug treatment are the major challenges for businesses.
 

Based on drug class, worldwide antiviral drugs industry is divided into DNA polymerase inhibitors, protease inhibitors, reverse transcript inhibitors, neuraminidase inhibitors, and others. Among these, others segment was assessed at USD 5 billion in 2020 and is anticipated to grow rapidly between 2021-2027 due to growing utilization of combination therapy for enhancing treatment efficacy.
 

Speaking of indication, the market sphere is fragmented into influenza, hepatitis, HIV aids, coronavirus infection, herpes simplex virus, and others. Among these, influenza segment is speculated to witness 4.3% CAGR between 2021-2027 owing to rising occurrence of seasonal flu, especially in the U.S., and emergence of new strains and subsequent requirement for new drugs.
 

As per type, the business domain is bifurcated into branded and generic, among which, the former held 70% of global antiviral drugs market share in 2020 and is estimated to showcase lucrative growth trends over the analysis timeframe. Higher efficiency of branded drugs and their production by leading companies are factors contributing to this growth.
 

Moving on to age group, the industry is segmented into adult, pediatric, and geriatric. Among these, the foremost segment captured 32% market share in 2020 and is expected to record considerable gains between 2021-2027. Affordable cost of therapy and rising prevalence of sexually transmitted diseases are the factors attributable to this growth.
 

Regionally speaking, North America market is projected to expand substantially between 2021-2027 owing to rising incidences of COVID-19, and strong presence of leading drug manufacturers for combating HIV and COVID-19.

Mylan N.V., Gilead Sciences Inc., Cipla limited, Johnson & Johnson, Sun Pharmaceutical Industries Limited, GlaxoSmithKline plc, Aurobindo Pharma Ltd., AbbVie Inc., Bristol-Myers Squibb Co. and Merck & Co. Inc. are the key players influencing the overall antiviral drugs market dynamics.